VCYT Stock Analysis: Veracyte | NASDAQ
Diagnostics & Research | NASDAQ, USA | Market Cap: 4.043m USD | 12M Return: 45.4% | US92337F1075 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 50.9M
Qual. Beats: 2
Rev. Trend: 99.6%
Qual. Beats: 7
Warnings
No concerns identified
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Veracyte, Inc. is a molecular diagnostics company that develops and commercializes genomic tests designed to resolve diagnostic ambiguity in cancer. The companys test portfolio targets several of the most common cancers, including thyroid (Afirma), prostate (Decipher Prostate), bladder (Decipher Bladder), breast (Prosigna), and lung (Percepta Nasal Swab). In addition to its proprietary assays, Veracyte offers nCounter analysis system services, which provide laboratories with gene expression analysis capabilities. The company sells its tests in the United States and internationally, reflecting a global commercialization strategy typical of specialty diagnostics firms.
Originally incorporated in 2006 as Calderome, Inc., the company adopted the Veracyte name in March 2008 and is headquartered in South San Francisco, California. Veracyte trades on NASDAQ under the ticker VCYT and is classified within the GICS Health Care sector, specifically the Biotechnology sub-industry. Its business model centers on selling high-value genomic tests to clinicians and hospital laboratories, where reimbursement is typically secured from public and private payers, a defining feature of the molecular diagnostics industry.
- Decipher Prostate test volume drives double-digit revenue growth
- Medicare expands reimbursement coverage for Afirma and Decipher genomic classifiers
- Prosigna breast cancer assay acquisition broadens oncology diagnostics portfolio
| Net Income: 126.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA 3.08 > 1.0 |
| NWC/Revenue: 65.95% < 20% (prev 76.15%; Δ -10.21% < -1%) |
| CFO/TA 0.11 > 3% & CFO 173.9m > Net Income 126.8m |
| Net Debt (-329.8m) to EBITDA (110.8m): -2.98 < 3 |
| Current Ratio: 5.56 > 1.5 & < 3 |
| Outstanding Shares: last quarter (82.8m) vs 12m ago 3.88% < -2% |
| Gross Margin: 72.35% > 18% (prev 68.53%; Δ 3.82% > 0.5%) |
| Asset Turnover: 39.56% > 50% (prev 36.20%; Δ 3.36% > 0%) |
| Interest Coverage Ratio: 89.3k > 6 (EBIT TTM 89.3m / Interest Expense TTM 1.00k) |
| A: 0.24 (Total Current Assets 467.9m - Total Current Liabilities 84.2m) / Total Assets 1.57b |
| B: -0.24 (Retained Earnings -377.6m / Total Assets 1.57b) |
| C: 0.06 (EBIT TTM 89.3m / Avg Total Assets 1.47b) |
| D: 10.24 (Book Value of Equity 1.43b / Total Liabilities 140.0m) |
| Altman-Z'' = 11.98 = AAA |
| DSRI: 1.01 (Receivables 56.8m/47.8m, Revenue 581.8m/495.1m) |
| GMI: 0.95 (GM 68.53% / 72.35%) |
| AQI: 1.05 (AQ_t 0.66 / AQ_t-1 0.63) |
| SGI: 1.17 (Revenue 581.8m / 495.1m) |
| TATA: -0.03 (NI 126.8m - CFO 173.9m) / TA 1.57b) |
| Beneish M = -2.91 (Cap -4..+1) = A |
As of November 05, 2026, the stock is trading at USD 52.52 with a total of 1,834,513 shares traded. Over the past week, the price has changed by +4.39%, over one month by +10.17%, over three months by +13.17% and over the past year by +45.40%.
Current recommended Stop Loss: 49.60 (which is 5.6% or 1.2 ATR below the current price).
Veracyte has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy VCYT.
- StrongBuy: 9
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 59.7 | 13.7% |
P/E Trailing = 35.9214
P/E Forward = 26.3158
P/S = 7.195
P/B = 2.8366
Revenue TTM = 581.8m USD
EBIT TTM = 89.3m USD
EBITDA TTM = 110.8m USD
Long Term Debt = 33.9m USD (estimated: total debt 40.7m - short term 6.81m)
Short Term Debt = 6.81m USD (from shortTermDebt, last quarter)
Debt = 40.7m USD (from shortLongTermDebtTotal, last quarter) (leases 40.1m already included)
Net Debt = -329.8m USD (calculated: Debt 40.7m - CCE 370.5m)
Enterprise Value = 3.71b USD (4.04b + Debt 40.7m - CCE 370.5m)
Interest Coverage Ratio = 89.3k (Ebit TTM 89.3m / Interest Expense TTM 1.00k)
EV/FCF = 23.00x (Enterprise Value 3.71b / FCF TTM 161.4m)
FCF Yield = 4.35% (FCF TTM 161.4m / Enterprise Value 3.71b)
FCF Margin = 27.74% (FCF TTM 161.4m / Revenue TTM 581.8m)
Net Margin = 21.80% (Net Income TTM 126.8m / Revenue TTM 581.8m)
Gross Margin = 72.35% ((Revenue TTM 581.8m - Cost of Revenue TTM 160.9m) / Revenue TTM)
Gross Margin QoQ = 70.58% (prev 72.21%)
Tobins Q-Ratio = 2.36 (Enterprise Value 3.71b / Total Assets 1.57b)
Interest Expense / Debt = 0.00% (Interest Expense 1.00k / Debt 40.7m)
Taxrate = 2.71% (1.85m / 68.2m)
NOPAT = 86.9m (EBIT 89.3m * (1 - 2.71%))
Current Ratio = 5.56 (Total Current Assets 467.9m / Total Current Liabilities 84.2m)
Debt / Equity = 0.03 (Debt 40.7m / totalStockholderEquity, last quarter 1.43b)
Debt / EBITDA = -2.98 (Net Debt -329.8m / EBITDA 110.8m)
Debt / FCF = -2.04 (Net Debt -329.8m / FCF TTM 161.4m)
Total Stockholder Equity = 1.37b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.63% (Net Income 126.8m / Total Assets 1.57b)
RoE = 9.27% (Net Income TTM 126.8m / Total Stockholder Equity 1.37b)
RoCE = 6.37% (EBIT 89.3m / Capital Employed (Equity 1.37b + L.T.Debt 33.9m))
RoIC = 5.93% (NOPAT 86.9m / Invested Capital 1.47b)
WACC = 8.45% (E(4.04b)/V(4.08b) * Re(8.54%) + D(40.7m)/V(4.08b) * Rd(0.00%) * (1-Tc(0.03)))
Discount Rate = 8.54% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 94.65 | Cagr: 3.17%
[DCF] Terminal Value 77.63% ; FCFF base≈136.1m ; Y1≈156.1m ; Y5≈229.7m
[DCF] Fair Price = 46.32 (EV 3.39b - Net Debt -329.8m = Equity 3.72b / Shares 80.4m; r=8.45% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 1.21 | # QB: 2
Revenue Correlation: 99.61 | Revenue CAGR: 18.83% | SUE: 1.97 | # QB: 7
EPS current Quarter (2026-09-30): EPS=0.41 | Chg30d=-0.46% | Revisions=-25% | Analysts=11
EPS current Year (2026-12-31): EPS=1.91 | Chg30d=-0.24% | Revisions=+0% | GrowthEPS=+7.2% | GrowthRev=+14.8%
EPS next Year (2027-12-31): EPS=1.94 | Chg30d=-0.40% | Revisions=-17% | GrowthEPS=+1.8% | GrowthRev=+11.2%
[Analyst] Revisions Ratio: -22% (up=2, down=4)